ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-OR57

Phase 3 Study of Maribavir (MBV) vs. Investigator-Assigned Therapy (IAT) for Refractory/Resistant (R/R) Cytomegalovirus (CMV) Infection Post-Transplant: Analysis of Kidney Recipients and Renal Safety

Session Information

Category: Transplantation

  • 1902 Transplantation: Clinical


  • Shihab, Fuad S., University of Utah Health Care, Salt Lake City, Utah, United States
  • Avery, Robin K., Johns Hopkins University Division of Infectious Diseases, Baltimore, Maryland, United States
  • Blumberg, Emily, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
  • Haririan, Abdolreza, University of Maryland, Baltimore, Maryland, United States
  • Wu, Jingyang, Shire Human Genetic Therapies, Inc., a Takeda company, Lexington, Massachusetts, United States
  • Sundberg, Aimee K., Shire Human Genetic Therapies, Inc., a Takeda company, Lexington, Massachusetts, United States

Risk of nephrotoxicity limits antiviral use for treatment (tx) of transplant recipients with CMV infection. We report efficacy (including sub-analysis of kidney recipients) and renal safety data from a phase 3 study of MBV vs IAT in patients (pts) with R/R CMV infection (NCT02931539).


Transplant recipients (≥12y) with CMV infection (screening plasma DNA≥910IU/mL) R/R to prior tx (failure to achieve>1log10 decrease in CMV DNA after≥14days±genotyped resistance) were randomized 2:1 MBV (400mg BID):IAT (val/ganciclovir,foscarnet[FOS],cidofovir) for 8wks. Primary endpoint:confirmed CMV clearance at end of Wk8 (plasma DNA<137IU/mL in 2 consecutive tests≥5days apart). Key secondary endpoint:CMV clearance and symptom control at end of Wk8 maintained through Wk16. Group differences were adjusted for baseline CMV DNA level+solid organ/hematopoietic cell transplant where applicable. Subgroup analysis of kidney recipients was conducted. Tx-emergent adverse events (TEAEs) were assessed (safety set).


More MBV (randomized set: 235 MBV, 117 IAT[47 FOS]) pts achieved the primary (55.7% vs 23.9% IAT; adjusted difference[AD] 32.8%, 95%CI 22.8–42.7;p<0.001) and key secondary endpoint (18.7% vs 10.3% IAT; AD 9.5%, 95%CI 2.0–16.9;p=0.013). For kidney recipients (74 MBV, 32 IAT), 59.5% MBV vs 34.4% IAT pts achieved CMV clearance (AD 26.7%, 95%CI 7.5–45.9). Rates of TEAEs were similar between MBV and IAT (Table). Dysgeusia was the most frequent TEAE with MBV (37.2%, IAT 3.4% pts). Tx-related TEAE of increased immunosuppressant drug level was reported in 6%pts treated with MBV (IAT 0%pts). Renal and urinary TEAE rates were lower for MBV (17.1%pts) than IAT (26.7%pts[FOS 44.7%pts]). A lower proportion of pts had tx-related acute kidney injury (AKI) with MBV (1.7%) than IAT (7.8%[FOS 19.1%]). Pts in the IAT arm discontinued tx due to AKI (5.2%[FOS 12.8%]); no pts treated with MBV discontinued tx due to renal TEAEs.


Maribavir was superior to IAT for achievement of clearance of R/R CMV infection among transplant recipients, with consistent benefit in kidney recipients. Rates of renal TEAEs were lower with MBV than IAT.

Overall and renal TEAEs and tx-related TEAEs occurring in ≥5% of patients in the MBV or IAT arms (safety set)
n (%) of patientsTEAETx-related TEAE
Any TEAE or tx-related TEAE

Any renal and urinary TEAEa

Acute kidney injuryb
228 (97.4)

40 (17.1)

20 (8.5)
106 (91.4)

31 (26.7)

11 (9.5)
141 (60.3)

4 (1.7)

4 (1.7)
57 (49.1)

15 (12.9)

9 (7.8)
aSystem organ class. Included adverse events coded using MedDRA, version 23.0; bPreferred term.
IAT, Investigator-assigned therapy; MBV, maribavir; TEAE, treatment-emergent adverse event; tx, treatment.


  • Commercial Support